Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,296,940
  • Shares Outstanding, K 134,677
  • Annual Sales, $ 42,070 K
  • Annual Income, $ -130,300 K
  • EBIT $ -110 M
  • EBITDA $ -112 M
  • 60-Month Beta 1.72
  • Price/Sales 31.69
  • Price/Cash Flow N/A
  • Price/Book 8.33

Options Overview Details

View History
  • Implied Volatility 234.01% (-60.07%)
  • Historical Volatility 67.17%
  • IV Percentile 64%
  • IV Rank 27.03%
  • IV High 777.13% on 05/12/25
  • IV Low 32.80% on 09/04/25
  • Expected Move (DTE 12) 0.89 (9.27%)
  • Put/Call Vol Ratio 16.67
  • Today's Volume 106
  • Volume Avg (30-Day) 105
  • Put/Call OI Ratio 2.17
  • Today's Open Interest 2,765
  • Open Int (30-Day) 5,045
  • Expected Range 8.74 to 10.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.31
  • Number of Estimates 6
  • High Estimate -0.28
  • Low Estimate -0.34
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +11.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.37 +30.66%
on 11/07/25
11.20 -14.02%
on 11/24/25
+2.12 (+28.23%)
since 11/05/25
3-Month
6.25 +54.08%
on 09/10/25
11.20 -14.02%
on 11/24/25
+2.69 (+38.76%)
since 09/05/25
52-Week
1.03 +834.95%
on 05/08/25
11.20 -14.02%
on 11/24/25
+6.16 (+177.52%)
since 12/05/24

Most Recent Stories

More News
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled...

TNGX : 9.63 (-2.73%)
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 9.63 (-2.73%)
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–  – Combination studies with RAS(ON) inhibitors ongoing, data...

TNGX : 9.63 (-2.73%)
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the...

TNGX : 9.63 (-2.73%)
Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 9.63 (-2.73%)
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –  – Combination studies with RAS(ON) inhibitors ongoing, data...

TNGX : 9.63 (-2.73%)
Biomarker-Driven Therapies And AI Technologies Transform $312B Precision Oncology Market

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Biomarker-driven approaches enhance the likelihood of identifying optimal patient populations and streamline...

CORT : 86.11 (+1.71%)
ARAY : 0.9855 (-3.38%)
KURA : 11.95 (-0.25%)
GTBP : 0.6094 (-3.24%)
TNGX : 9.63 (-2.73%)
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 9.63 (-2.73%)
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...

TNGX : 9.63 (-2.73%)
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative...

TNGX : 9.63 (-2.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 10.34
2nd Resistance Point 10.16
1st Resistance Point 9.90
Last Price 9.63
1st Support Level 9.46
2nd Support Level 9.28
3rd Support Level 9.02

See More

52-Week High 11.20
Last Price 9.63
Fibonacci 61.8% 7.32
Fibonacci 50% 6.11
Fibonacci 38.2% 4.91
52-Week Low 1.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar